Akin to all βAR-blocking agents, the predominant action of carvedilol is to counter the stimulating effects of endogenous catecholamines by antagonizing β1 and β2ARs, but it also possesses some residual agonistic activity, proposed to explain its uniqueness over other β-blockers in heart failure clinical trials27. Here, ADRB2 is linked to heart failure.